VLS — Vita Life Sciences Share Price
0.000.00%
Last trade - 00:00HealthcareBalancedSmall CapSuper Stock
- AU$97.47m
- AU$79.12m
- AU$66.89m
- 97
- 70
- 87
- 96
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.48 | ||
| Price to Tang. Book | 2.48 | ||
| Price to Free Cashflow | 13.61 | ||
| Price to Sales | 1.42 | ||
| EV to EBITDA | 6.94 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 27.14% | ||
| Return on Equity | 20.24% | ||
| Operating Margin | 15.6% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 41.15 | 42.45 | 46.48 | 57.1 | 66.89 | n/a | n/a | 12.45% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -23.03 | +29.97 | +103.09 | +34.48 | -15.93 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Vita Life Sciences Limited (Vita Life) is a pharmaceutical and healthcare company. The Company is involved in formulating, packaging, sales and distributing vitamins and supplements. Its core business is the development and distribution of over-the-counter (OTC) medicines, as well as complementary and alternative medicines, dietary supplements and health foods under various brand names throughout Australia, Malaysia, Singapore, Thailand, Vietnam, China and Indonesia. Its brand portfolio includes Herbs of Gold, VitaHealth, VitaScience and VitaLife. Herbs of Gold brand produces premium herbal, mineral, vitamin and superfood products. VitaHealth brand offers a comprehensive range of nutritional products that cater to every health need, from inner wellness to outer radiance. VitaScience is a vivacious nutritional supplement brand that offers practitioner strength quality formulations. Its subsidiaries include Vita Healthcare Asia Pacific Sdn Bhd, Herbs of Gold Sdn Bhd and others.
Directors
- Henry Townsing NEC
- Lim Sung Tie CEO (57)
- Chin Khoo CFO
- Andrew O'Keefe MDR
- Tanakorn Chalermjiripas GMG
- Edmund Sim GMG
- Gregory Ralph NED (64)
- Shane Teoh NED
- Last Annual
- December 31st, 2022
- Last Interim
- June 30th, 2023
- Incorporated
- November 5th, 1986
- Public Since
- August 23rd, 2007
- No. of Shareholders
- 880
- No. of Employees
- 124
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Australian Stock Exchange - SEATS
- Shares in Issue
- 56,504,612
- Address
- Unit 1 102 Bath Road, Kirrawee, SYDNEY, 2232
- Web
- https://vitalifesciences.com/
- Phone
- +61 295452633
- Auditors
- Nexia Sydney Audit Pty Limited
Upcoming Events for VLS
Vita Life Sciences Ltd Annual Shareholders Meeting
Similar to VLS
Acrux
Australian Stock Exchange - SEATS
AFT Pharmaceuticals
Australian Stock Exchange - SEATS
Althea group
Australian Stock Exchange - SEATS
Auscann group
Australian Stock Exchange - SEATS
Biome Australia
Australian Stock Exchange - SEATS
FAQ
What is the Vita Life Sciences share price?
As of Today at 18:23 UTC, shares in Vita Life Sciences are trading at AU$1.73. This share price information is delayed by 15 minutes.
How has the Vita Life Sciences share price performed this year?
Shares in Vita Life Sciences last closed at AU$1.73 and the price had moved by +12.75% over the past 365 days. In terms of relative price strength the Vita Life Sciences share price has outperformed the ASX All Ordinaries Index by +15.83% over the past year.
What are the analyst and broker recommendations for Vita Life Sciences?
There is no consensus recommendation for this security.
What is the Vita Life Sciences dividend yield?
The Vita Life Sciences dividend yield is 3.62% based on the trailing twelve month period.
Does Vita Life Sciences pay a dividend?
Last year, Vita Life Sciences paid a total dividend of AU$0.06, and it currently has a trailing dividend yield of 3.62%. We do not have any data on when Vita Life Sciences is to next pay dividends.
When does Vita Life Sciences next pay dividends?
We do not have data on when Vita Life Sciences is to next pay dividends. The historic dividend yield on Vita Life Sciences shares is currently 3.62%.
How do I buy Vita Life Sciences shares?
To buy shares in Vita Life Sciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Vita Life Sciences?
As of the previous close price of AU$1.73, shares in Vita Life Sciences had a market capitalisation of AU$97.47m.
Where are Vita Life Sciences shares listed?
Here are the trading details for Vita Life Sciences:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: VLS
What kind of share is Vita Life Sciences?
Based on an overall assessment of its quality, value and momentum Vita Life Sciences is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Vita Life Sciences share price forecast for 2023?
We could not find analyst target price data for this security.
What is the trend in the Vita Life Sciences share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Vita Life Sciences. Over the past six months, its share price has outperformed the ASX All Ordinaries Index by +13.77%.
As of the last closing price of AU$1.73, shares in Vita Life Sciences were trading +6.32% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Vita Life Sciences PE Ratio?
The Vita Life Sciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$1.73.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Vita Life Sciences?
Vita Life Sciences' management team is headed by:
- Henry Townsing - NEC
- Lim Sung Tie - CEO
- Chin Khoo - CFO
- Andrew O'Keefe - MDR
- Tanakorn Chalermjiripas - GMG
- Edmund Sim - GMG
- Gregory Ralph - NED
- Shane Teoh - NED